Static Chart Kymera Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
32.11 ^USD	-0.16%		-5.70%	+26.12%

06-01	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	CI
05-22	Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting	CI

Duration

Period